BCRX - Company ID 0000882796
The table below shows BIOCRYST PHARMACEUTICALS INC's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $874.84M | $450.71M | $331.41M | $270.83M | $157.17M | $17.81M |
| Cost of revenue | $19.07M | $12.27M | $4.48M | $6.41M | $7.23M | $1.55M |
| Gross profit | - | - | - | - | - | - |
| R&D | $166.13M | $174.64M | $216.57M | $253.30M | $208.81M | $122.96M |
BIOCRYST PHARMACEUTICALS INC reported annual revenue of $874.84M for fiscal year 2025. That is up 94.1% from $450.71M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $26.35M (FY 2016) to $874.84M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $348.65M |
| $266.35M |
| $214.07M |
| $159.37M |
| $118.82M |
| $67.93M |
| Operating income | $340.99M | -$2.54M | -$103.71M | -$148.44M | -$177.72M | -$174.76M |
| Income tax | $3.53M | $1.93M | $310.00K | $2.73M | $2.25M | $0.00 |
| Net income | $263.86M | -$88.88M | -$226.54M | -$247.12M | -$184.06M | -$182.81M |
| EPS (diluted) | $1.21 | -$0.43 | -$1.18 | -$1.33 | -$1.03 | -$1.09 |